Essential Planning LLC. Takes $4.28 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Essential Planning LLC. purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,230 shares of the medical equipment provider’s stock, valued at approximately $4,282,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new stake in Intuitive Surgical in the fourth quarter worth about $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Intuitive Surgical in the fourth quarter worth about $31,000. MidAtlantic Capital Management Inc. acquired a new stake in Intuitive Surgical in the third quarter worth about $33,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical in the fourth quarter worth about $36,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ISRG shares. UBS Group upped their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Barclays upped their price target on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Evercore ISI upped their price target on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Insider Activity at Intuitive Surgical

In other news, CFO Jamie Samath sold 94 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total value of $53,684.34. Following the sale, the chief financial officer now owns 2,630 shares in the company, valued at approximately $1,502,019.30. This trade represents a 3.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,209 shares of company stock valued at $11,928,127. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $497.30 on Thursday. The firm has a market cap of $177.13 billion, a PE ratio of 77.58, a PEG ratio of 5.85 and a beta of 1.43. The firm’s 50 day moving average price is $569.42 and its 200 day moving average price is $531.60. Intuitive Surgical, Inc. has a twelve month low of $364.17 and a twelve month high of $616.00.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.